LindseyElizabethRoekerMD

PubMed

• HMA/VEN treatment modifications and associated outcomes in-mutant AML.
  Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav K Gupta, P Dayand Borge
  Leukemia & Lymphoma. 2025-02-01
• 1 citations
  Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
  Mazyar Shadman, Monika Salkar, Bhavini Srivastava, Sudeep Karve, Bruno Emond
  Leukemia & Lymphoma. 2025-01-01
• Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
  Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach
  Haematologica. 2025-01-01

Abstracts/Posters

• Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...
  Lindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...
  Lindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Treatment Discontinuation Patterns for Patients with CLL in the Real-World Settings: Results from a Multi-Center Study
  Lindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Toxicities and Outcomes of Acalabrutinib-Treated Patients with Chronic Lymphocytic Leukemia: A Retrospective Analysis of Real World Patients
  Lindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalid...
  Lindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Lindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Lindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Time to Second Treatment As a Proxy for Overall Survival in CLL/SLL: Identifying Risk Factors to Help Guide Treatment Selection
  Lindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Treatment Sequences and Outcomes of Patients with CLL Treated with Venetoclax and Other Novel Agents Post Introduction of Novel Therapies
  Lindsey E. Roeker, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Allogeneic Stem Cell Transplantation (alloHSCT) for Chronic Lymphocytic Leukemia (CLL) in the Era of Novel Agents 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019